Abeona Therapeutics Inc.

NasdaqCM ABEO

Abeona Therapeutics Inc. Current Liabilities for the quarter ending September 30, 2024

Abeona Therapeutics Inc. Current Liabilities is NA for the quarter ending September 30, 2024. Current liabilities are obligations that are expected to be settled within one year, including accounts payable, short-term debt, and other current liabilities.

Key data

Date	Current Liabilities	Total Non-Current Liabilities	Shareholders' Equity	Long-Term Debt

NasdaqCM: ABEO

Abeona Therapeutics Inc.

CEO	Dr. Vishwas Seshadri M.B.A., Ph.D.
IPO Date	Sept. 19, 1980
Location	United States
Headquarters	1330 Avenue of the Americas
Employees	84
Sector	Healthcare
Industries Biotechnology

Description

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A; ABO-201 to treat CLN3 disease; ABO-401 for the treatment of cystic fibrosis; and ABO-50X for the treatment of genetic eye disorders. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1974 and is headquartered in New York, New York.

Key trends

Past 5 years